Navigation Links
Pharmacyclics Reports Financial Results for Fiscal 2010 and for Fourth Quarter 2010
Date:9/13/2010

in a registered direct offering, $50.8 million, net of approximately $1.6 million in offering costs. Pharmacyclics' Chairman and CEO, Robert W. Duggan, participated in the offering in the amount of $7.0 million.

Fiscal 2011 GuidanceAs a direct result of the success we are generating, accelerated investment for the purpose of collapsing the time required to achieve our goals is called for.

We expect net cash expenditures of approximately $32.5 million which equates to $35.0 million of operational expenses offset by $2.0 million in cash from R&D revenue and $0.5 million from the French Government in the form of a tax return.  Approximately 80% of the clinical expenditures in fiscal 2011 will be Btk inhibitor related.

Financial projections involve a high level of uncertainty due to, among other factors, the variability involved in predicting requirements of early stage research programs and clinical trials, the potential for entering into partnering arrangements or strategic collaborations, the timing of U.S. Food and Drug Administration (FDA) decisions and share-based compensation expense.

Commenting on the announcement, Bob Duggan, CEO of Pharmacyclics, said, "Whether you judge by the rapid pace of patient enrollment in BTK inhibitor PCI 32765 clinical trials, broad enthusiasm over the patient outcomes to date, strengthening the balance sheet through equity capital raises, or stock price appreciation year to date, fiscal 2010 was an awesome year. Rest assured the entire Pharmacyclics team is dedicated to producing even better results in fiscal 2011."

Dr. John Byrd, Ohio State University's Director of the Comprehensive Cancer Center, Division of Hematology, added,  "It is always nice when pre-clinical studies such as those recently published by Pharmacyclics in PNAS translate to positive results in clinical trials of lymphoma and CLL patients that we and others are now observing.
The labo
'/>"/>

SOURCE Pharmacyclics
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14

Related medicine technology :

1. Pharmacyclics Announces Data and Publication Characterizing Highly-Selective HDAC Inhibitor
2. Pharmacyclics Announces Preclinical Results Supporting Development of Its Novel Btk Inhibitor in Immune Mediated Diseases
3. Pharmacyclics Reports Multiple Presentations at AACR on Its HDAC and Selective HDAC Inhibitors
4. Pharmacyclics Novel Factor VIIa Inhibitor Demonstrates Potential Inhibition of Tumor Growth in Multiple Types of Cancer
5. Pharmacyclics Novel Btk Inhibitor Shows Efficacy in Preclinical Models of Rheumatoid Arthritis and Lymphoma
6. Pharmacyclics Announces Completion of Phase 1 Clinical Trial of Factor VIIa Inhibitor PCI-27483
7. Pharmacyclics, Inc. Announces Closing of a Private Financing With the Principals of Pacific Biopharma Group, Ltd.
8. Pharmacyclics Initiates Phase 1 Clinical Trial of Novel Oral Btk Inhibitor for Refractory B-cell Non-Hodgkins Lymphoma
9. Pharmacyclics announces Global Strategic Alliance with Les Laboratoires Servier
10. Pharmacyclics to Present at Merriman Curhan Fords Investor Summit 2009
11. Pharmacyclics Announces Poster Presentations and Clinical Update at the 51st Annual Meeting of the American Society of Hematology
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/17/2014)... DALLAS , September 17, 2014 ... Electronics Market by Component (Sensor, Battery, Memory Device, Display, ... and Fitness & Wellness), and by Geography - Global ... of medical electronics market is expected to reach $56.50 ... from 2014 to 2020. Browse 235 market ...
(Date:9/17/2014)... 2014  NuView Life Sciences, Inc. (NuView) announced ... agreement with Otsuka Pharmaceutical Co., Ltd. (Otsuka) to ... biomarker to detect cancers of the breast and ... diagnostic-imaging applications. NuView retains all rights for the ... urine screen applications. Under the terms ...
(Date:9/17/2014)... Isis Pharmaceuticals, Inc. (NASDAQ: ... $4 million milestone payment from Achaogen, Inc. (NASDAQ: ... of a Phase 3 study of plazomicin in ... infections.  The Phase 3 study is designed as ... safety of plazomicin compared to colistin in patients ...
Breaking Medicine Technology:Medical Electronics Market Worth $56.50 Billion by 2020 2Medical Electronics Market Worth $56.50 Billion by 2020 3Medical Electronics Market Worth $56.50 Billion by 2020 4NuView Life Sciences Enters Global Licensing Agreement With Otsuka Pharmaceutical 2NuView Life Sciences Enters Global Licensing Agreement With Otsuka Pharmaceutical 3NuView Life Sciences Enters Global Licensing Agreement With Otsuka Pharmaceutical 4NuView Life Sciences Enters Global Licensing Agreement With Otsuka Pharmaceutical 5Isis Pharmaceuticals Earns $4 Million from Achaogen for the Initiation of a Phase 3 Study of Plazomicin 2Isis Pharmaceuticals Earns $4 Million from Achaogen for the Initiation of a Phase 3 Study of Plazomicin 3
... Belt Technologies, Inc., a Pittsburgh based medical device company ... use in orthopaedic and neurosurgery procedures, has closed on ... financing. The round was led by private investors ... Works (Pittsburgh) and consisted of both new investments and ...
... Sept. 30 Law firm Clifford Chance, as international counsel, ... with Wyeth under China,s Anti-Monopoly Law. The clearance was issued ... , Competition approval from the Chinese authorities was one of ... The EU has already approved the deal; decisions are awaited ...
Cached Medicine Technology:Blue Belt Technologies, Inc. Closes Series A Financing 2Blue Belt Technologies, Inc. Closes Series A Financing 3Clifford Chance Advises Pfizer on Conditional Clearance in China of Its Merger with Wyeth 2
(Date:9/17/2014)... (PRWEB) September 17, 2014 In Pretrial ... that “bi-weekly telephonic discovery conferences would be beneficial in ... conferences through mid-December. “At the end of December,” the ... the need for additional conferences. , “The plain ... that there is still much to be discussed as ...
(Date:9/17/2014)... 2014 (HealthDay News) -- Positive messages about the health ... the habit, a new study suggests. Although smokers ... "loss-framed" messages about the harmful effects of smoking, researchers ... want benefit more from "gain-framed," or positive, messages about ... concluded that using a mix of both types of ...
(Date:9/17/2014)... Many countries choose to kill all infected poultry ... number of poultry exceeds 10 billion in China. Epidemic ... huge losses. Therefore, it is quite necessary to immunize ... vaccines have been used for more than 10 years ... use H5N1 avian influenza vaccines voluntarily 10 years ago ...
(Date:9/17/2014)... (PRWEB) September 17, 2014 StartX ... revealed 12 companies raising rounds of funding at its ... few hundred investors and media, was the first such ... located next to the university. The presentations were delivered ... adjacent to StartX-QB3 Labs, a 2,000 square foot life ...
(Date:9/17/2014)... The Delta Dental Community Care Foundation announced today ... Health Foundation: America’s ToothFairy (NCOHF) to support oral health ... Zone Program® in California. , The Orange County NCOHF ... local constituent groups and stakeholders in a comprehensive approach ... its devastating effects on local families. The support of ...
Breaking Medicine News(10 mins):Health News:Transvaginal Mesh Lawsuit News: New Order in C.R. Bard MDL Sets Schedule of Conferences for September to December, the Rottenstein Law Group LLP Reports 2Health News:More Than One Kind of Message May Convince Smokers to Quit, Study Says 2Health News:China Avian Influenza Vaccine Industry 2014-2018 Research Report Now Available at LifeScienceIndustryResearch.com 2Health News:China Avian Influenza Vaccine Industry 2014-2018 Research Report Now Available at LifeScienceIndustryResearch.com 3Health News:Stanford-affiliated StartX Showcases Startups, New HQ, and Growth of Stanford-StartX Fund 2Health News:Stanford-affiliated StartX Showcases Startups, New HQ, and Growth of Stanford-StartX Fund 3Health News:Stanford-affiliated StartX Showcases Startups, New HQ, and Growth of Stanford-StartX Fund 4Health News:Stanford-affiliated StartX Showcases Startups, New HQ, and Growth of Stanford-StartX Fund 5Health News:Stanford-affiliated StartX Showcases Startups, New HQ, and Growth of Stanford-StartX Fund 6Health News:Delta Dental Community Care Foundation Donation to America's ToothFairy Helps Deliver Critical Services 2
... multi-center U.S. registry on the efficacy of carotid stenting ... are at high risk for standard surgical therapy.// ... CAPTURE (Carotid ACCULINK/ACCUNET Post Approval Trial to Uncover Rare ... Cardiology’s 55th Annual Session in Atlanta. The multi-center study ...
... with a friend will be more beneficial to health than ... Elizabeth Gould at Harvard University compared the costs and benefits ... and found that contrary to accepted wisdom, jogging was not ... Daily Mail. ,The researchers carried out series of ...
... Hopkins University School of Medicine said that genetic material in ... // , The researchers feel that it very ... of mutated human genes. ,Jef Boeke described about ... the yeast cells which is necessary for the stability of ...
... spells doom for global economic growth. According to bank economist ... a dent of two to six percentage out of global ... rate reductions and older populations, which will lead to continued ... Burns, has been getting Bay Street and investors to gear ...
... at the end of the tunnel. Those infected with human ... workplaces. // Employers will have to face legal charges if ... ,HIV causes acquired immune deficiency syndrome. The ministry of ... of HIV/AIDS, which will seek to protect the rights of ...
... and 170 suspected cases of meningococcimia or meningitis in New ... who are taking strict measures to check the spread of ... sure that family members and neighbors of infected persons are ... also distributing leaflets to educate people about the symptoms of ...
Cached Medicine News:Health News:Carotid Stenting Can Help Patients With Silent Disease 2Health News:Carotid Stenting Can Help Patients With Silent Disease 3Health News:Carotid Stenting Can Help Patients With Silent Disease 4
... anesthesia workstation provides an intelligent approach ... to provide true clinical benefits to ... the art computer technology integrates hemodynamic ... color touchscreen display panel. The open ...
... Cost effective technology in anesthesia., ,Whether ... manual ventilation, the operating theater or as ... integrated monitoring, the Aliseo product family allows ... ,With three product models, you have ...
... in facilities where space is a premium ... gas delivery technologies with an ergonomic and ... functionality of the Draeger Infinity patient monitoring ... workplace environment that is a sound investment ...
... A new level of excellence and ... advanced anesthesia delivery system with basic ventilation ... industry leading excellence of the Aestiva/5 Anesthesia ... compact design - it features a configurable ...
Medicine Products: